LINEAGE CELL THERAPEUTICS IN (LCTX)

US53566P1093 - Common Stock

0.558  +0.06 (+11.16%)

After market: 0.552 -0.01 (-1.08%)

LINEAGE CELL THERAPEUTICS IN

NYSEARCA:LCTX (12/20/2024, 8:21:56 PM)

After market: 0.552 -0.01 (-1.08%)

0.558

+0.06 (+11.16%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%50%
Sales Q2Q%203.29%
CRS6.07
6 Month-38.21%
Overview
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Ins Owners0.44%
Inst Owners50.34%
Market Cap122.99M
Shares220.42M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts81.43
Short Float %9.78%
Short Ratio9.31
IPO03-05 1992-03-05
Stock Screener Links
Screen Image

American Stock Exchange Stock Screener

Find more stocks on American Stock Exchange

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

LCTX Daily chart

Company Profile

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 75 full-time employees. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

Company Info

LINEAGE CELL THERAPEUTICS IN

2173 Salk Avenue, Suite 200

Carlsbad CALIFORNIA 92008

P: 15105213390

CEO: Brian M. Culley

Employees: 72

Website: https://lineagecell.com/

LCTX Twits

Here you can normally see the latest stock twits on LCTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example